Rafik El Beblawy, M.D

IM Hospitalist, ex chief resident @UABMedicine. Huntsville. AOA Member @AOA_society 🇪🇬 @CairoUniv, National Cancer Institute ⏩#aspiring_oncologist #medtwitter

[Rafik El Beblawy, M.D @rafikelbebmd]

Finally the board certification is here! It’s a reminder of this year’s humbling achievements as 2024 is coming to an end. Setbacks were definitely a part of the story but will remain as stepping stones for what’s next.
#MedTwitter #MedEd @ABIMcert @AOA_society

[LARVOL @Larvol]

We're presenting at @ASCO 2026!

Evaluating AI decision support in a rapidly evolving therapeutic landscape: EGFR-mutant metastatic NSCLC.

📍 Poster Board #548
🕘 9:00 AM CT

If you're attending ASCO 2026, stop by our poster and connect with the team. We look forward to the discussion.

Abstract link 👉 https://t.co/cBYIDqsGmD

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #NSCLC #LCSM | @Jani_Chinmay | @Jud_Prz | @Ankitowledge |
@Debarat07333230 | @Kyle__Edwards | @rafikelbebmd | @brunolarvol | @lungoncdoc | @Latinamd | @ADesaiMD | @GlopesMd | @dan_morgen

[OncoDaily IO @OncoDailyIO]

Evolving Role of Perioperative Immunotherapy in Resectable NSCLC - Rafik ElBeblawy (@rafikelbebmd)

https://t.co/bT3OHYjXsy

#OncoDaily #Oncology #Cancer #Health #Medicine #Immunotherapy #MedX

[Rafik El Beblawy, M.D @rafikelbebmd]

🚨 Excited to share our editorial commentary in Journal of Thoracic Disease on the AEGEAN trial and the evolving role of perioperative immunotherapy in resectable NSCLC. 🫁
https://t.co/CR4ifbNVZr

@ADesaiMD @Jani_Chinmay
#LungCancer #NSCLC #Immunotherapy #ThoracicOncology

[LARVOL @Larvol]

It was a pleasure collaborating with Rafik ElBeblawy (@rafikelbebmd), Chinmay Jani (@Jani_Chinmay), and Aakash Desai (@ADesaiMD) on our recently published article, "The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities."

The article presents a data-driven analysis of 681 clinical trials evaluating 183 bispecific antibodies in solid tumors, using @Larvol CLIN to map key trends. The study highlights the rapid expansion since 2019, a strong focus on immune checkpoint and oncogene-directed bispecifics, and gaps in biomarker use across the global pipeline.

Read the full study here: https://t.co/7ShMEhDuMd

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #SolidTumors #BispecificAntibodies #BsAbs | @Jud_Prz

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

Credit to @rafikelbebmd and @Jani_Chinmay for the heavy lifting on this! Amazing teamwork!! @Larvol @Jud_Prz @brunolarvol for the support!

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🚨 Bispecific antibodies (BsAbs) in solid tumors are rapidly reshaping oncology.

Our pipeline analysis using @Larvol CLIN shows:
▫️681 trials, 183 BsAbs (📈 doubled since 2019)
▫️ Heavy focus on GI, lung, breast & GYN cancers
▫️ Dominant targets: PD1–CTLA4 (32%), PD1–VEGF, EGFR–MET
▫️ Only 38% of trials biomarker-selected
▫️ Innovation largely driven by biotech, not big pharma
@CancerMedicineJ @OncoAlert @oncodaily
🔗: https://t.co/LHqiH4gSxS

[Rafik El Beblawy, M.D @rafikelbebmd]

Superb teamwork @Jani_Chinmay @Larvol @Jud_Prz and mentorship by Dr @ADesaiMD

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🚨 Bispecific antibodies (BsAbs) in solid tumors are rapidly reshaping oncology.

Our pipeline analysis using @Larvol CLIN shows:
▫️681 trials, 183 BsAbs (📈 doubled since 2019)
▫️ Heavy focus on GI, lung, breast & GYN cancers
▫️ Dominant targets: PD1–CTLA4 (32%), PD1–VEGF, EGFR–MET
▫️ Only 38% of trials biomarker-selected
▫️ Innovation largely driven by biotech, not big pharma
@CancerMedicineJ @OncoAlert @oncodaily
🔗: https://t.co/LHqiH4gSxS

[Rafik El Beblawy, M.D @rafikelbebmd]

@Sai_Wannaphut @MayoClinic @RManochakian @IMG_Oncologists @HemOncFellows @oncodaily @hemeoncfellow @TheNRMP @MedicalwatchHQ @ASCO @ASH_hematology @HemOncWomenDocs Congratulations Sai 👏👏

[Ramy Sedhom, MD, FASCO @ramsedhom]

Few will read @TheLancet report, but it is SO powerful I am going to tweet the entire abstract https://t.co/idxEg0risM

"Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care.

[Rafik El Beblawy, M.D @rafikelbebmd]

@HemOncFellows @IMG_Oncologists @ASCOTECAG @OncBrothers #IMGOncCop #MedTwitter #GIoncology #Immunotheraoy #PrecisionMedicine @uabmedicine @UABHemOncFellow

[Rafik El Beblawy, M.D @rafikelbebmd]

🔥New publication alert 🚨...Proud to share our review on role of cytokine-based immunotherapy in GI cancers in Cytokine & Growth Factor Reviews.

https://t.co/ye50ah4pCw

Grateful to Drs @MehmetAkce2 & @MallaMidhun for mentorship.

[Vincent Rajkumar @VincentRK]

Just out in the New England Journal of Medicine!

Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM https://t.co/7dza0YrFh5

5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark!

How to test and manage patients. Who needs bone marrow exams and scans. It’s all in here!

MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear MGCS, MGRS etc. in this Review

@myelomaMD and I have tried to keep every sentence in this Review simple and easy to follow. #MGUSVR

[American Board Certified Doctors for Egypt @doctor4egypt]

Meet Our mentors ✨️
Dr. @rafikelbebmd
#match2026

[Oncology Brothers @OncBrothers]

Lung Cancer Highlights from #ASCO25 w/ @StephenVLiu

✅ #CM816
✅ Timings of ICI
✅ #neoADAURA
✅ #IMForte
✅ #DeLLphi304

Full Discussion:
- https://t.co/52xiM5hTM9
- Also on the “Oncology Brothers” podcast

#lcsm @ASCO #OncTwitter #MedTwitter

[Rafik El Beblawy, M.D @rafikelbebmd]

Exciting work presented by @royaryam at #ASCO25 on the research productivity of IMG Hem-Onc fellows in the U.S. 📊 Insightful data that highlights contributions and challenges in academic oncology! 💼🌎 #MedTwitter #IMG #HemeOnc #IMGCoP @IMG_Oncologists @HemOncFellows

[LARVOL @Larvol]

Proud to share our abstracts for @ASCO 2025!
Thank you to our co-authors, advisors, and collaborators.

#ASCO25 #CancerReaserch #Oncology #Myeloma #SolidTumors #BreastCancer #ASCO2025 #LARVOL

@Jud_Prz | Kamal Saini | @LucaCantiniMD | Shakti Ramkissoon | @cancerdocko | Laura Vidal Boixader | Isagani Chico | @brunolarvol | Mark Gramling | Carmen Besliu | @ShankarAbhishek | @rafikelbebmd | @Jani_Chinmay | @DocSamDeshmukh | @SanadAlhushki | @MehmetAkce2 | @VivekSubbiah | @ADesaiMD

[Arya Roy @royaryam]

Excited to present our research on academic productivity of IMG fellows as an oral presentation at #ASCO25. Grateful for the opportunity to spotlight IMG contributions! @IMG_Oncologists @DrChoueiri @NazliDizman @ZiadBakouny @KarunNeupaneMD @ArdeshirFatemeh @OhioStateMedOnc

[Rafik El Beblawy, M.D @rafikelbebmd]

@IMG_Oncologists
Don’t miss @royaryam presenting a compelling oral abstract on #IMG research productivity and the #HemOncFellowship journey—June 2nd at 9:45 AM, Room E350. #ASCO2025
Grateful to be part of this incredible team

[Rafik El Beblawy, M.D @rafikelbebmd]

@Jani_Chinmay @Jud_Prz

[Rafik El Beblawy, M.D @rafikelbebmd]

@IMG_Oncologists
Thrilled to be part of #ASCO2025, contributing to six posters—including one as first author! #OnlinePublication #BsAbs #SolidTumors
Grateful to @ADesaiMD for your outstanding mentorship & this incredible opportunity. It was a pleasure collaborating with @Larvol.